{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:01:21Z","timestamp":1791234081013,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00204-025-04054-8","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:32:27Z","timestamp":1747470747000},"page":"2855-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic activation and cytotoxicity of carvedilol mediated by cytochrome P450s in vitro and in vivo"],"prefix":"10.1007","volume":"99","author":[{"given":"Shibo","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-2147","authenticated-orcid":false,"given":"Jiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"Suppl 2","key":"4054_CR1","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1007\/BF01409475","volume":"38","author":"W Bartsch","year":"1990","unstructured":"Bartsch W, Sponer G, Strein K, M\u00fcller-Beckmann B, Kling L, B\u00f6hm E, Martin U, Borbe HO (1990) Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 38(Suppl 2):S104\u2013S107. https:\/\/doi.org\/10.1007\/BF01409475","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"4054_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.31.3.289","volume":"31","author":"KM Bertelsen","year":"2003","unstructured":"Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metabol Dispos 31(3):289\u2013293. https:\/\/doi.org\/10.1124\/dmd.31.3.289","journal-title":"Drug Metabol Dispos"},{"issue":"Suppl 1","key":"4054_CR3","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1007\/BF00207620","volume":"70","author":"MR Bristow","year":"1992","unstructured":"Bristow MR, Larrabee P, M\u00fcller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD (1992) Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig 70(Suppl 1):S105\u2013S113. https:\/\/doi.org\/10.1007\/BF00207620","journal-title":"Clin Investig"},{"issue":"2","key":"4054_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1527-3466.2001.tb00061.x","volume":"19","author":"J Cheng","year":"2001","unstructured":"Cheng J, Kamiya K, Kodama I (2001) Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 19(2):152\u2013171. https:\/\/doi.org\/10.1111\/j.1527-3466.2001.tb00061.x","journal-title":"Cardiovasc Drug Rev"},{"issue":"1","key":"4054_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jhep.2018.01.001","volume":"69","author":"L Dakhoul","year":"2018","unstructured":"Dakhoul L, Ghabril M, Chalasani N (2018) Drug-induced chronic liver injury. J Hepatol 69(1):248\u2013250. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.001","journal-title":"J Hepatol"},{"issue":"4","key":"4054_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s002280050628","volume":"55","author":"TW Gehr","year":"1999","unstructured":"Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH (1999) The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 55(4):269\u2013277. https:\/\/doi.org\/10.1007\/s002280050628","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4054_CR7","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1208\/aapsj080112","volume":"8","author":"FP Guengerich","year":"2006","unstructured":"Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8(1):E101\u2013E111. https:\/\/doi.org\/10.1208\/aapsj080112","journal-title":"AAPS J"},{"issue":"11","key":"4054_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1345\/aph.10239","volume":"35","author":"KO Hagmeyer","year":"2001","unstructured":"Hagmeyer KO, Stein J (2001) Hepatotoxicity associated with carvedilol. Ann Pharmacother 35(11):1364\u20131366. https:\/\/doi.org\/10.1345\/aph.10239","journal-title":"Ann Pharmacother"},{"issue":"6","key":"4054_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.dmpk.2016.08.007","volume":"31","author":"M Iwaki","year":"2016","unstructured":"Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H (2016) Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet 31(6):425\u2013432. https:\/\/doi.org\/10.1016\/j.dmpk.2016.08.007","journal-title":"Drug Metab Pharmacokinet"},{"issue":"16","key":"4054_CR10","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2165\/00003495-200363160-00006","volume":"63","author":"GM Keating","year":"2003","unstructured":"Keating GM, Jarvis B (2003) Carvedilol: a review of its use in chronic heart failure. Drugs 63(16):1697\u20131741. https:\/\/doi.org\/10.2165\/00003495-200363160-00006","journal-title":"Drugs"},{"issue":"5","key":"4054_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1067\/mhj.2002.121265","volume":"143","author":"S L\u00e4er","year":"2002","unstructured":"L\u00e4er S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Meibohm B, Weil J (2002) Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143(5):916\u2013922. https:\/\/doi.org\/10.1067\/mhj.2002.121265","journal-title":"Am Heart J"},{"issue":"2","key":"4054_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/toxsci\/kfad088","volume":"196","author":"H Lastuvkova","year":"2023","unstructured":"Lastuvkova H, Nova Z, Hroch M, Alaei Faradonbeh F, Schreiberova J, Mokry J, Faistova H, Stefela A, Dusek J, Kucera O, Hyspler R, Dohnalkova E, Bayer RL, Hirsova P, Pavek P, Micuda S (2023) Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis. Toxicol Sci 196(2):200\u2013217. https:\/\/doi.org\/10.1093\/toxsci\/kfad088","journal-title":"Toxicol Sci"},{"issue":"10","key":"4054_CR13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1124\/dmd.114.059261","volume":"42","author":"D Lin","year":"2014","unstructured":"Lin D, Li C, Peng Y, Gao H, Zheng J (2014) Cytochrome p450-mediated metabolic activation of diosbulbin B. Drug Metabol Dispos 42(10):1727\u20131736. https:\/\/doi.org\/10.1124\/dmd.114.059261","journal-title":"Drug Metabol Dispos"},{"key":"4054_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2024.12.009","volume":"404","author":"S Liu","year":"2025","unstructured":"Liu S, Zhao G, Xu Y, Wang Y, Ding Z, Li W, Peng Y, Zheng J (2025) Metabolic activation and hepatic cytotoxicity of osthole mediated by cytochrome P450 enzymes. Toxicol Lett 404:1\u20138. https:\/\/doi.org\/10.1016\/j.toxlet.2024.12.009","journal-title":"Toxicol Lett"},{"issue":"4","key":"4054_CR15","first-page":"569","volume":"3","author":"M Metra","year":"2007","unstructured":"Metra M, Nodari S, Bordonali T, Milani P, Lombardi C, Bugatti S, Fontanella B, Verzura G, Danesi R, Dei Cas L (2007) Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Ther Clin Risk Manag 3(4):569\u2013578","journal-title":"Ther Clin Risk Manag"},{"issue":"21","key":"4054_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure US Carvedilol Heart Failure Study Group. New Engl J Med 334(21):1349\u20131355. https:\/\/doi.org\/10.1056\/NEJM199605233342101","journal-title":"New Engl J Med"},{"issue":"1","key":"4054_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","volume":"49","author":"Y Parmentier","year":"2019","unstructured":"Parmentier Y, Pothier C, Hewitt N, Vincent L, Caradec F, Liu J, Lin F, Trancart MM, Guillet F, Bouaita B, Chesne C, Walther B (2019) Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes\u2122 model. Xenobiotica 49(1):22\u201335. https:\/\/doi.org\/10.1080\/00498254.2017.1422156","journal-title":"Xenobiotica"},{"issue":"9377","key":"4054_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Investigators COMET (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (London, England) 362(9377):7\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(03)13800-7","journal-title":"Lancet (London, England)"},{"issue":"5","key":"4054_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s0006-2952(98)00268-8","volume":"57","author":"AD Rodrigues","year":"1999","unstructured":"Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465\u2013480. https:\/\/doi.org\/10.1016\/s0006-2952(98)00268-8","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4054_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000490205","volume":"26","author":"J Rua","year":"2019","unstructured":"Rua J, Prata AR, Marques R, Silva R, Gomes B, Fraga J, Fortuna J (2019) Carvedilol-induced liver injury, a rare cause of mixed hepatitis: a clinical case. GE Port J Gastroenterol 26(3):196\u2013201. https:\/\/doi.org\/10.1159\/000490205","journal-title":"GE Port J Gastroenterol"},{"issue":"10","key":"4054_CR21","first-page":"958","volume":"26","author":"WH Schaefer","year":"1998","unstructured":"Schaefer WH, Politowski J, Hwang B, Dixon F Jr, Goalwin A, Gutzait L, Anderson K, DeBrosse C, Bean M, Rhodes GR (1998) Metabolism of carvedilol in dogs, rats, and mice. Drug Metabol Dispos 26(10):958\u2013969","journal-title":"Drug Metabol Dispos"},{"key":"4054_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0091-679x(08)61797-5","volume":"13","author":"PO Seglen","year":"1976","unstructured":"Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29\u201383. https:\/\/doi.org\/10.1016\/s0091-679x(08)61797-5","journal-title":"Methods Cell Biol"},{"issue":"8","key":"4054_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1124\/dmd.112.049940","volume":"41","author":"Y Shirasaka","year":"2013","unstructured":"Shirasaka Y, Chang SY, Grubb MF, Peng CC, Thummel KE, Isoherranen N, Rodrigues AD (2013) Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug Metabol Dispos 41(8):1566\u20131574. https:\/\/doi.org\/10.1124\/dmd.112.049940","journal-title":"Drug Metabol Dispos"},{"key":"4054_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.freeradbiomed.2019.04.026","volume":"137","author":"N Shu","year":"2019","unstructured":"Shu N, Lorentzen LG, Davies MJ (2019) Reaction of quinones with proteins: Kinetics of adduct formation, effects on enzymatic activity and protein structure, and potential reversibility of modifications. Free Radical Biol Med 137:169\u2013180. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.04.026","journal-title":"Free Radical Biol Med"},{"issue":"6","key":"4054_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/hep4.1064","volume":"1","author":"YI Yamashita","year":"2017","unstructured":"Yamashita YI, Imai K, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Baba H (2017) Idiosyncratic drug-induced liver injury: a short review. Hepatol Commun 1(6):494\u2013500. https:\/\/doi.org\/10.1002\/hep4.1064","journal-title":"Hepatol Commun"},{"issue":"1","key":"4054_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1208\/s12249-020-01906-7","volume":"22","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Wang X, Xue H, Huang B, Lin Z, Cai Z (2021) Determination and comparison of the solubility, oil-water partition coefficient, intestinal absorption, and biliary excretion of carvedilol enantiomers. AAPS PharmSciTech 22(1):43. https:\/\/doi.org\/10.1208\/s12249-020-01906-7","journal-title":"AAPS PharmSciTech"},{"key":"4054_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2022.05.008","volume":"365","author":"N Zhang","year":"2022","unstructured":"Zhang N, Zhou S, Zhang Z, Li W, Peng Y, Zheng J (2022) Evidence for adduction of biologic amines with reactive metabolite of 8-epidiosbulbin E acetate in vitro and in vivo. Toxicol Lett 365:1\u201310. https:\/\/doi.org\/10.1016\/j.toxlet.2022.05.008","journal-title":"Toxicol Lett"},{"issue":"5","key":"4054_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0009-9236(95)90036-5","volume":"57","author":"HH Zhou","year":"1995","unstructured":"Zhou HH, Wood AJ (1995) Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57(5):518\u2013524. https:\/\/doi.org\/10.1016\/0009-9236(95)90036-5","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"4054_CR29","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1021\/acs.jmedchem.9b02073","volume":"63","author":"S Zhou","year":"2020","unstructured":"Zhou S, Li W, Tian M, Zhang N, Yang X, Li W, Peng Y, Zheng J (2020) Metabolic activation of pirfenidone mediated by cytochrome P450s and sulfotransferases. J Med Chem 63(15):8059\u20138068. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b02073","journal-title":"J Med Chem"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-025-04054-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:52:20Z","timestamp":1750859540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-025-04054-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4054"],"URL":"https:\/\/doi.org\/10.1007\/s00204-025-04054-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}